Home › Funds › Atle Fund Management AB › IONS

Atle Fund Management AB position in IONS

IONIS PHARMACEUTICALS INC · Health Care

Atle Fund Management AB reported holding 137,131 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$10.9M, representing 2.93% of its reported portfolio and ranking #12 among its reported holdings. Atle Fund Management AB has disclosed IONS holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)137.13K sh
Reported value held$10.87M
Portfolio Weight2.93%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's IONS position evolved

Atle Fund Management AB first disclosed a stake in IONS in Q4 2023 at 24,243 shares (US$1.2M). The position peaked in Q2 2026 at 137,131 shares, worth US$10.9M. Across 7 filings, Atle Fund Management AB increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 137,131 shares valued at US$10.9M — an increase of 109,258 shares quarter over quarter.. Notable position changes include a 163% increase in Q1 2024 (shares rose 10% over the following quarter), a 103% increase in Q3 2024 (shares fell 13% over the following quarter), a 392% increase in Q2 2026 (shares fell 44% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 24.24K $1.23M New
Q1 2024 63.79K $2.77M Add
Q2 2024 40.69K $1.94M Reduce
Q3 2024 82.69K $3.31M Add
Q4 2025 92.38K $7.31M New
Q1 2026 27.87K $9.40M Reduce
Q2 2026 137.13K $10.87M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IONS and 13F data

IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Tweedy, Browne Co LLC (US$180.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IONS

All IONS fund holders →

FAQ

How long has Atle Fund Management AB held IONS?

Atle Fund Management AB has disclosed IONS holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

What is Atle Fund Management AB's current position in IONS?

As of Q2 2026, Atle Fund Management AB holds 137.13K shares of IONS (IONIS PHARMACEUTICALS INC), valued at $10.87M, representing 2.93% of its reported portfolio and ranking #12.

Has Atle Fund Management AB been buying or selling IONS?

In the latest 13F filing (Q2 2026), Atle Fund Management AB increased its position in IONS. The position peaked in Q2 2026 at 137.13K shares.

Which other funds hold IONS?

Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Tweedy, Browne Co LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.